Select Page



Clinical Advisory Board

Professor Stewart Factor

Dr. Factor is Professor of Neurology, Director of the Movement Disorders Program and Vance Lanier Chair of Neurology at Emory University School of Medicine.  He received his DO Degree in 1982, completed his Neurology Residency at Albany Medical Center in 1986 and Movement Disorder Fellowship at University of Miami in 1988.  He is past Chair of the Movement Disorders Section of the American Academy of Neurology and member of the Committee On Sections Executive Committee.  He has edited three textbooks: “Parkinson’s Disease: Diagnosis and Clinical Management” first & second editions and “Drug-induced Movement Disorders” as well as authoring over 250 peer reviewed articles.  Areas of research interest include evaluation of biomarkers in PD (Funded by the Michael J Fox Foundation), freezing of gait in PD (private funding), clinical trials previously site PI for the NINDS supported NeuroNext network), participation in a consortium to study gene environment interactions in PD, and tardive dyskinesia.  As program director he is also the fellowship program director in movement disorders and has mentored 15 fellows in the last 10 years.

Michael Grundman, MD, MPH

President and CEO, Global R&D Partners, LLC

Dr. Grundman is the President and Chief Executive Officer at Global R&D Partners, LLC, a consulting firm that works closely with pharmaceutical and biotechnology companies to develop novel agents for the diagnosis and treatment of serious and life threatening diseases. He previously served as Vice President of Clinical Development at Janssen Alzheimer Immunotherapy, LLC, and Elan Pharmaceuticals, Inc. Prior to joining the pharmaceutical industry, Dr. Grundman was Associate Director of the Alzheimer’s Disease Cooperative Study (ADCS) at the University of California, San Diego (UCSD) and is currently an Adjunct Professor of Neurosciences at UCSD. He received his BA from New York University with Honors in Biochemistry. He obtained an MD and Neurology training at the Albert Einstein College of Medicine and a Master of Public Health degree from Columbia University. Dr. Grundman previously served on the FDA Peripheral and Central Nervous System Advisory Committee and is an inventor on a number of patents related to Alzheimer’s disease therapy. He lectures frequently at national and international scientific meetings and has published over 80 articles related to Alzheimer’s disease and dementia.

Robert A. Hauser, MD, MBA

Dr. Robert Hauser is Professor of Neurology at the University of South Florida College of Medicine, in Tampa, Florida. He serves as Director of the USF Parkinson’s Disease and Movement Disorders Center, a Parkinson Foundation Center of Excellence. Dr. Hauser earned a medical degree from Temple University School of Medicine, in Philadelphia, Pennsylvania, and completed neurology training at the Eastern Virginia Graduate School of Medicine, in Norfolk, Virginia. Dr. Hauser completed a fellowship in Movement Disorders at the University of South Florida and became Center Director in 1994. Dr. Hauser has authored or co-authored more than 300 peer-reviewed publications and is one of the world’s most cited Parkinson’s Disease investigators. He is Past Chairman of the Interventional Neurology Section of the American Academy of Neurology, has served on the executive committee of the Parkinson Study Group, and was a member of the steering committee for the NIH sponsored Neuroprotective Exploratory Trials in Parkinson’s Disease program (NET-PD). Dr. Hauser lectures frequently at scientific meetings and served as Chairman of the 2009 World Federation of Neurology International Congress on Parkinson’s Disease and Related Disorders. He has extensive expertise in clinical trial design and execution. Outcome measures that he developed have become the gold standard for use in clinical trials. He maintains an active patient practice and has been voted a Top Doctor by his peers every year since 1993. His primary research interest is the development of new medical and surgical treatments for Parkinson’s disease and other movement disorders.

Professor Rajesh Pahwa, MD

Dr. Pahwa is a Professor of Neurology at the University of Kansas Medical Center and Director of the Parkinson’s Disease and Movement Disorder Center with The University of Kansas Health System. Together those two entities create the region’s premier academic medical center. He received his M.B.B.S. (M.D.) degree at Seth G.S. Medical College, University of Bombay, India. He completed an internship in medicine at Baylor College of Medicine followed by a residency in Neurology at Baylor College of Medicine, Houston, Texas. Dr. Pahwa’s research interests are centered around the various aspects of Parkinson’s disease and essential tremor. He is currently involved in studies related to medical and surgical forms of therapies for Parkinson’s disease and essential tremor. Dr. Pahwa has published more than 250 peer-reviewed articles, chapters and abstracts in leading neurology and movement disorder journals. He has conducted more than 75 clinical trials related to Parkinson’s disease and other movement disorders. He is the co-editor of “Handbook of Parkinson’s Disease,” 3rd and 4th editions; “Therapy of Parkinson’s Disease,” 3rd edition; and “Handbook of Essential Tremor and other Tremor Disorders.” He is co-author of the book “Parkinson’s Disease: Questions and Answers,” 4th edition. The Movement Disorders Clinic, led by Dr. Rajesh Pahwa, offers diagnostic and treatment services for persons with Parkinson’s disease and related disorders.

Professor Olivier Rascol, MD, PhD

Dr. Rascol has run the Toulouse Clinical Research Centre since 1994 and the Toulouse European Space Clinic since 1998. He has also run a research group on motricity in the Research Unit INSERM U825. Dr Rascol is a neuropharmacologist specializing in Parkinson’s disease and movement disorders, drug development for Parkinson’s disease and functional neuroimaging. Dr Rascol has been actively involved in the development of several marketed antiparkinsonian medications (ropinirole, rasagiline, entacapone, safinamide, pramipexole ER, amantadine ER). He is an external advisor for French and European scientific organizations, patients’ associations, drug agencies and international pharmaceutical companies. Professor Rascol was the Secretary of the international Movement Disorders Society (2006-2009) and the chair of the MDS-ES (2013-2015) and is a member of the WFN Research Committee on Parkinsonism and Related Disorders. Dr Rascol is Associate-Editor for the Journal Fundamental and Clinical Pharmacology and the Movement Disorder Journal and is or been a member of the editorial board of Lancet Neurology, Neurology, the European Journal of Neurology, the Evidence Medicine.  He has published more than 450 peer reviewed articles and invited to give more than 400 lectures.

Professor Tan Eng King, MD

Dr. Tan is a senior consultant neurologist and research director at the National Neuroscience Institute. Dr. Tan also serves as a professor at both the Duke-NUS Medical School and the Lee Kong Chian School of Medicine. Dr. Tan is an editor of the European Journal of Neurology, and Parkinson’s disease Journal and has written over 300 peer reviewed research articles focused mainly on Parkinson’s disease. He has received several accolades and awards including the David Marsden Lectureship and Yoshi Mizuno lectureship awards from the International Movement Disorders Society (MDS). He is a founding member of the MDS Asian Oceanic Section. Dr. Tan’s clinical interest is in neurodegenerative disorders including Parkinson’s disease, essential tremor and other related disorders. He also runs a botulinum toxin clinic managing patients with various neurological disorders. Dr. Tan’s research interests include clinical and neuroimaging studies, functional genomics and experimental therapeutics in movement disorders.